These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 30504401

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Regulation of aldo-keto-reductase family 1 B10 by 14-3-3ε and their prognostic impact of hepatocellular carcinoma.
    Liu TA, Jan YJ, Ko BS, Wu YJ, Lu YJ, Liang SM, Liu CC, Chen SC, Wang J, Shyue SK, Liou JY.
    Oncotarget; 2015 Nov 17; 6(36):38967-82. PubMed ID: 26516929
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma.
    Jin GZ, Yu WL, Dong H, Zhou WP, Gu YJ, Yu H, Yu H, Lu XY, Xian ZH, Liu YK, Cong WM, Wu MC.
    J Hepatol; 2013 Sep 17; 59(3):510-7. PubMed ID: 23665285
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma.
    Sato S, Genda T, Hirano K, Tsuzura H, Narita Y, Kanemitsu Y, Kikuchi T, Iijima K, Wada R, Ichida T.
    Liver Int; 2012 Oct 17; 32(9):1382-90. PubMed ID: 22681639
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication.
    Murata A, Genda T, Ichida T, Amano N, Sato S, Tsuzura H, Sato S, Narita Y, Kanemitsu Y, Shimada Y, Hirano K, Iijima K, Wada R, Nagahara A, Watanabe S.
    World J Gastroenterol; 2016 Sep 07; 22(33):7569-78. PubMed ID: 27672277
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Upregulation of focal adhesion kinase by 14-3-3ε via NFκB activation in hepatocellular carcinoma.
    Ko BS, Jan YJ, Chang TC, Liang SM, Chen SC, Liu TA, Wu YM, Wang J, Liou JY.
    Anticancer Agents Med Chem; 2013 May 07; 13(4):555-62. PubMed ID: 22934705
    [Abstract] [Full Text] [Related]

  • 13. 14-3-3ε overexpression contributes to epithelial-mesenchymal transition of hepatocellular carcinoma.
    Liu TA, Jan YJ, Ko BS, Liang SM, Chen SC, Wang J, Hsu C, Wu YM, Liou JY.
    PLoS One; 2013 May 07; 8(3):e57968. PubMed ID: 23483955
    [Abstract] [Full Text] [Related]

  • 14. Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
    Matkowskyj KA, Bai H, Liao J, Zhang W, Li H, Rao S, Omary R, Yang GY.
    Hum Pathol; 2014 Apr 07; 45(4):834-43. PubMed ID: 24656094
    [Abstract] [Full Text] [Related]

  • 15. Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis.
    Tsuzura H, Genda T, Sato S, Murata A, Kanemitsu Y, Narita Y, Ishikawa S, Kikuchi T, Mori M, Hirano K, Iijima K, Wada R, Ichida T.
    Int J Mol Sci; 2014 Apr 17; 15(4):6556-68. PubMed ID: 24747592
    [Abstract] [Full Text] [Related]

  • 16. High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
    Wang YY, Qi LN, Zhong JH, Qin HG, Ye JZ, Lu SD, Ma L, Xiang BD, Li LQ, You XM.
    Sci Rep; 2017 Feb 09; 7():42199. PubMed ID: 28181486
    [Abstract] [Full Text] [Related]

  • 17. IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma.
    Cheng BY, Lau EY, Leung HW, Leung CO, Ho NP, Gurung S, Cheng LK, Lin CH, Lo RC, Ma S, Ng IO, Lee TK.
    Cancer Res; 2018 May 01; 78(9):2332-2342. PubMed ID: 29483095
    [Abstract] [Full Text] [Related]

  • 18. AKR1B10 expression characteristics in hepatocellular carcinoma and its correlation with clinicopathological features and immune microenvironment.
    Ma LN, Ma Y, Luo X, Ma ZM, Ma LN, Ding XC.
    Sci Rep; 2024 May 27; 14(1):12149. PubMed ID: 38802416
    [Abstract] [Full Text] [Related]

  • 19. Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
    Kanno M, Kawaguchi K, Honda M, Horii R, Takatori H, Shimakami T, Kitamura K, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Kaneko S.
    J Gastroenterol; 2019 Jun 27; 54(6):549-557. PubMed ID: 30707282
    [Abstract] [Full Text] [Related]

  • 20. Expression of metallothionein-1 and metallothionein-2 as a prognostic marker in hepatocellular carcinoma.
    Park Y, Yu E.
    J Gastroenterol Hepatol; 2013 Sep 27; 28(9):1565-72. PubMed ID: 23662831
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.